miR-212通过靶向NRP1调节结肠癌SW480肿瘤干细胞样特性和免疫应答北大核心CSCD

目的:探讨miR-212在SW480肿瘤干细胞样特性和免疫应答中的调控作用,并初步分析其调控机制。方法:结肠癌SW480细胞分别转染mimic、miR-NC或miR-212-5p,RT-PCR检测神经纤毛蛋白1(NRP1)和miR-212-5p表达水平并进行相关性分析;TargetScan预测miR-212-5p潜在靶向基因NRP1,荧光素酶实验验证靶向关系;SW480细胞单独或联合转染miR-212-5p和pcDNA-NRP1,RT-PCR检测miR-212-5p和NRP1 mRNA表达水平,Western blot检测NRP1蛋白表达水平;流式细胞术分选干细胞阳性标记(CD44+)比例,Western blot检测性别决定区Y框蛋白2(SOX2)和富含亮氨酸重复单位的G蛋白偶联受体5(LGR5)蛋白表达;ELISA测定SW480细胞上清液中IL-6、TNF-α和IL-4蛋白含量,RT-PCR检测IL-6和IL-4 mRNA表达水平。结果:与Control组相比,miR-212-5p显著上调SW480肿瘤干细胞miR-212-5p表达(P<0.05),下调NRP1表达(P<0.05),抑制CD44+、SOX2、LFR5表达(P<0.05),促进炎症反应和免疫应答(P<0.05);与NRP1组相比,miR-212-5p明显抑制因NRP1上调的CD44+、SOX2和LGR5表达(P<0.05),促进因NRP1下调的炎症因子表达(P<0.05)。结论:miR-212-5p靶向抑制NRP1表达,调节结肠癌SW480肿瘤干细胞样特性和免疫应答。     

抗人PD-L1 单克隆抗体的制备及其应用

目的:获得能应用于临床诊断以及阻断PD-L1 与PD-1 结合的抗人PD-L1 单克隆抗体。方法:采用重组表达的人PD-L1 蛋白免疫BALB/ c 小鼠,通过杂交瘤细胞融合技术获得稳定分泌抗人PD-L1 单抗的阳性细胞株,ELISA 方法鉴定抗体的特异性、亲和力、亚型等方面特性;免疫印迹、间接免疫荧光方法对肿瘤细胞进行检测;肿瘤杀伤实验验证抗体阻断活性。结果:共获得2 株抗人PD-L1 单抗,抗体效价分别为1 2.56 106 和1 3 105 ,亲和力分别为1.5 109 L/ mol 和2.5 108 L/ mol,均与PD-L2 蛋白无交叉反应。免疫印迹、间接免疫荧光证实抗体有诊断作用。杀伤实验显示抗体有阻断作用。结论:共获得两株稳定分泌高效价、高特异性的抗人PD-L1 单抗的杂交瘤细胞株,能作为诊断抗体应用于肿瘤表型检测和预后有效性的评估。抗体的阻断功能可应用于联合CIK 细胞免疫治疗。     

登革病毒非结构蛋白NS1群特异性单克隆抗体的制备及初步应用

目的制备登革病毒NS1群特异性单克隆抗体,建立可检测登革病毒1～4型NS1抗原的ELISA检测法,为登革热的早期快速诊断奠定基础。方法应用毕赤酵母表达系统分泌表达登革病毒2型重组非结构蛋白NS1,以此为抗原免疫BABL/c小鼠,取其脾细胞与小鼠骨髓瘤细胞融合,经HAT选择培养、间接ELISA筛选和亚克隆,获得能稳定分泌登革病毒NS1群特异性单克隆抗体的杂交瘤细胞株;用所获得的单克隆抗体建立可检测1～4型登革病毒NS1抗原的双抗体夹心ELISA法。结果从登革病毒2型NS1重组毕赤酵母（Pichia Pastoris-NS1）中获得了大量纯化的登革病毒重组NS1蛋白;经免疫小鼠、细胞融合、间接ELISA筛选及3次亚克隆后,最终获得2株能高效分泌抗登革病毒NS1单克隆抗体的杂交瘤细胞株2D7B6B4和2D10E2F6,间接ELISA显示抗体效价高达1∶8000～1∶16000;ELISA及免疫荧光检测证实,其所分泌的抗体与1～4型登革病毒及其重组NS1蛋白均有特异性免疫反应,为登革病毒NS1群特异性单克隆抗体;两株单克隆抗体均为IgG2a亚类;初步建立了检测4个血清型登革病毒NS1抗原的双抗体夹心ELISA法。结论成功研制出两株能高效分泌抗登革病毒NS1群特异性单克隆抗体的杂交瘤细胞株。初步建立了可检测1～4型登革病毒NS1抗原的双抗体夹心ELISA检测法。     

葡萄胎病理相关基因F10编码蛋白单克隆抗体的制备与应用

目的 构建原核质粒表达葡萄胎相关新基因F10重组蛋白,分离纯化制备其单克隆抗体,并鉴定其生物学特性。方法用逆转录聚合酶链反应法从成人组织中扩增F10编码序列,将其克隆到p ET28a原核表达载体,在大肠杆菌BL21(DE3)内进行诱导表达F10基因重组蛋白。以纯化后的重组蛋白免疫Balb/c小鼠制备单克隆抗体。ELISA法检测杂交瘤细胞分泌F10单克隆抗体的效价和类型,免疫组织化学染色检测F10蛋白在葡萄胎及胎盘组织中的表达,鉴定制备F10单克隆抗体的特异性。结果 成功构建了p ET28a/F10原核表达质粒并获得高纯度的重组F10蛋白。筛选出3株能稳定分泌抗F10蛋白的单克隆抗体杂交瘤细胞系,其效价比高达1∶7.2×105,免疫球蛋白类型均为Ig G1类。免疫组织化学染色显示该抗体能特异结合葡萄胎及胎盘绒毛组织中的F10蛋白,且葡萄胎组织中F10蛋白的表达显著高于正常胎盘组织。结论 表达及纯化的重组F10蛋白纯度高,免疫原性强。以此为抗原制备的抗F10蛋白的单克隆抗体效价高、特异性强,可用于F10功能的进一步研究。     

抗凋亡抑制蛋白——survivin单克隆抗体的制备

目的制备抗 survivin蛋白单克隆抗体。方法以大肠杆菌表达的 survivin融合蛋白为抗原 ,免疫 Balb/c小鼠 ,通过细胞融合 ,建立分泌单克隆抗体的杂交瘤细胞系。结果获得了 6株稳定分泌单克隆抗体的杂交瘤细胞系。 6株单克隆抗体均能特异识别和结合大肠杆菌表达的 survivin融合蛋白 ,但其中仅有 3株能够结合肿瘤细胞系表达的天然 survivin蛋白 ,并与某些肿瘤细胞系中 5 0 0 0 0 u±分子量的未知蛋白存在交叉反应 ,与正常人外周血淋巴细胞样本未见任何反应。结论通过单克隆抗体的免疫印迹反应 ,可以观察 survivin特定分子量蛋白的表达 ,为深入研究该蛋白的细胞凋亡调控功能提供了工具。此外 ,这些单克隆抗体对于肿瘤诊断也具有一定应用价值。     

抗人大肠癌单克隆抗体的制备及应用

目的制备和纯化抗人大肠癌单克隆抗体(ND-1),分析其在大肠癌诊断中的应用价值。方法常规免疫小鼠制备腹水,腹水经离心和过滤后,应用G蛋白亲和层析法进行纯化。采用SDS-PAGE、间接免疫荧光(IFA)、间接ELISA检测纯化后抗体的纯度、活性、效价和特异性。并用免疫组织化学SP法检测在大肠癌组织中的表达。结果经SDS-PAGE分离可见两条相对分子质量(Mr)分别为55 000和25 000明显的两条蛋白条带。间接ELISA检测抗体效价为1∶1 000 000,ND-1抗体对表达相应抗原的大肠癌细胞株具有特异结合活性。人大肠癌组织切片经ND-1抗体免疫组织化学染色阳性率为82.9%,其中高分化腺癌阳性率为100%。结论应用G蛋白亲和层析法可以很好分离纯化鼠腹水中的IgG1亚型的单克隆抗体,抗体的纯度高,特异性强,生物学活性好,可望成为有效的肿瘤诊断和治疗的手段。     

hK6单克隆抗体制备及在胃和乳房肿瘤组织中的初步应用

目的:原核表达人组织激肽释放酶6(human kallikrein 6,hK6),采用杂交瘤技术制备其单克隆抗体,建立免疫组织化学方法,检测hK6在胃癌、乳腺癌组织中的表达情况.方法:通过原核表达hK6融合蛋白免疫BALB/c小鼠,采用杂交瘤技术制备特异性单克隆抗体,并用间接ELISA、SDS-PAGE及Western-blot鉴定抗体,protein A agarose亲和层析柱纯化抗体,并以此抗体建立免疫组织化学方法检测人胃癌、乳腺癌组织中hK6表达情况.结果:成功筛选出4株高分泌型特异性杂交瘤细胞株,其制备抗体可与hK6融合蛋白发生特异性结合;免疫组织学显示,hK6主要分布在胃癌细胞胞浆中,成阳性表达,而在癌旁胃黏膜中成阴性表达;在乳腺癌组织中定位于胞浆,成弱阳性表达,癌旁组织成阴性表达.结论:成功制备了高纯度、特异性的抗hK6单克隆抗体;该抗体为深入研究hK6功能和建立高特异性、高敏感性检测组织和体液中hK6的方法奠定基础.     

人抗P53蛋白单克隆抗体的制备及评价

目的制备获得人P53蛋白单克隆抗体,并应用于免疫组化检测。方法利用基因重组方法,将p53基因构建到原核质粒载体上并诱导表达,将收集获得的P53蛋白免疫小鼠,经细胞融合及亚克隆手段获得鼠源单克隆抗体,与商品化的抗体DO-1共同染色蜡块包埋的病理组织样本,比较二者的染色结果。结果在筛选获得的与DO-1检测结果相近的5株抗体内,取检测结果最接近的1株抗体5E10,经Protein A/G株纯化抗体,与收集获得的数例癌症组织蜡块进行免疫组化验证,发现结果均与DO-1的结果无明显差异。结论成功制备并筛选出1株人抗P53单克隆抗体,可用于免疫组化染色。     

抗RAET1G2单克隆抗体的研制和初步鉴定

目的:制备鼠源抗RAET1G2单克隆抗体,并对其特异性进行鉴定。方法:以原核表达的RAET1G2蛋白为抗原免疫BALB/c小鼠,运用B淋巴细胞杂交瘤技术制备抗RAET1G2单克隆抗体;用免疫双扩散方法鉴定Ig亚类;Western blot鉴定单克隆抗体的特异性。结果:获得了4株可分泌特异性抗RAET1G2抗体的杂交瘤细胞株7A11、9C6、10F9和12F8,Ig亚类均为IgG1。结论:制备的杂交瘤细胞株能稳定分泌特异性的抗RAET1G2抗体,并且所分泌的单克隆抗体都能识别天然的RAET1G蛋白,为进一步研究游离性的RAETlG2分子与肿瘤进展的关系以及分析各种肿瘤细胞表面的RAET1G表达情况创造了条件。     

胃癌中VEGF、NRP1和干细胞标志物CD44的表达及相关性

目的探讨VEGF、NRP1和干细胞标志物CD44在胃癌组织中的表达及三者间的相关性。方法应用高通量组织芯片技术和免疫组化SP法检测72例胃癌和52例正常胃组织中VEGF、NRP1和CD44蛋白的表达,并分析三者之间的相关性以及与胃癌临床病理特征的关系。结果 (1)胃癌组织中VEGF、NRP1和CD44蛋白阳性率分别为76.4%、66.7%、83.3%,三者在胃癌组织中的表达显著高于正常胃组织,差异均具有统计学意义(P均<0.01)。(2)VEGF、NRP1蛋白表达与胃癌浸润深度、淋巴结转移、临床分期有关(P均<0.05);CD44表达与Lauren分型、分化程度、淋巴结转移、临床分期有关(P均<0.05)。(3)胃癌组织中VEGF、NRP1和CD44蛋白的表达均呈正相关(rs=0.578,rs=0.278,rs=0.316,P均<0.05)。结论 VEGF、NRP1和干细胞标志物CD44在胃癌中均呈高表达,且与胃癌的恶性生物学行为密切相关。VEGF与NRP1之间可能存在协同作用,二者均与干细胞标志物CD44的表达密切相关,其具体机制有待进一步研究。     

Y14和Upf1在人乳腺癌细胞表达增强

目的 探讨Y14和Upf1在人乳腺癌细胞株和人乳腺癌组织表达情况及其意义。方法 应用免疫细胞化学、激光共聚焦方法测定Y14和Upf1在乳腺癌细胞株MCF-7、ZR-75-30、T47D、MDA-MB-435s、MDA-MB-453、MDA-MB-231与乳腺上皮细胞株HBL-100中的表达情况。结果 ⑴人乳腺癌细胞株中Y14和Upf1的表达均明显高于乳腺上皮细胞株（P＜0.05）。⑵在人乳腺癌细胞中,MDA-MB-231细胞株的Y14和Upf1表达明显高于MCF-7细胞（P＜0.05）。⑶Y14和Upf1在人乳腺癌组织表达增强（P＜0.05）。结论 Y14和Upf1在人乳腺癌细胞和人乳腺癌组织中的表达增强。     

CD147 monoclonal antibodies induce homotypic cell aggregation of monocytic cell line U937 via LFA-1/ICAM-1 pathway

CD147 is a 50 000-60 000 MW glycoprotein of the immunoglobulin superfamily broadly expressed on haemopoietic cell lines and peripheral blood cells. In the present study, six monoclonal antibodies (mAbs) directed against the CD147 protein were generated. The antigen defined by the generated CD147 mAbs is widely expressed on haemopoietic cell lines, peripheral blood cells and is a lymphocyte activation-associated cell surface molecule. The generated CD147 mAbs precipitated a broad protein band from U937 cells of 45 000-65 000 MW under reducing conditions. Functional analysis indicated that the CD147 mAbs markedly induced homotypic cell aggregation of U937 cells, but not K562 cells. The CD147 mAb-induced cell aggregation was inhibited by leucocyte function-antigen-1 (LFA-1) and intercellular adhesion molecule-1 (ICAM-1) mAbs. However, the expression of LFA-1 and ICAM-1 molecules on U937 was not altered by CD147 mAb treatment. The U937 cell aggregation induced by CD147 mAb was also inhibited by ethylenediamine tetra-acetic acid (EDTA), sodium azide and when incubated at 4 degrees. We therefore propose that the binding of CD147 mAb to CD147 molecule, which mimics the natural ligand binding, may generate intracellular signals that activate LFA-1/ICAM-1 intercellular adhesion pathway.     

Characterization and application of three novel monoclonal antibodies against human 4-1BB: distinct epitopes of human 4-1BB on lung tumor cells and immune cells

4-1BB, a member of the tumor necrosis factor receptor (TNFR) superfamily, is a costimulatory receptor that is primarily expressed on activated T cells and professional antigen-presenting cells. In this study, the expression pattern of 4-1BB on immunology cells and tumor cells was explored by flow cytometry using newly generated three anti-4-1BB monoclonal antibodies (mAbs; 6F9, 7D6, and 1G11), which bind to distinct 4-1BB epitopes. Compared with the available 4-1BB mAb 4B4-1 that recognized 4-1BB on activated T cells and monocytes, the novel mAbs also could recognize 4-1BB on some cancer cell lines, particularly on lung cancer cell lines such as SPC-A-1, H446, H460, and H1299 by flow cytometry analysis, western blot, and RT-PCR. Immunohistochemistry staining showed the 4-1BB was expressed on lung tumor tissue (33/35) but not on normal lung tissue (3/3). It was determined that 4-1BB was strictly expressed on lung cancer cells, which may provide information on the 4-1BB signal in tumor immunology mechanism.     

MicroRNA-365 inhibits growth,invasion and metastasis of malignant melanoma by targeting NRP1 expression

Objective: The role of miR-365 in cancer cells seemed controversial in previous studies. We thereby in this article aimed to define the role of miR-365 in malignant melanoma (MM) pathogenesis. Methods: We detected miR-365 expression in malignant melanoma cell lines and then investigated the effects of miR-365 on the metastasis and malignancy of melanoma cells. The correlation between miR-365 level and NRP1 (neuropilin1) was further investigated in clinical malignant melanoma specimens. Results: MiR-365 was strongly down-regulated in malignant melanoma (MM) tissues and cell lines, and its expression levels were associated with lymph node metastasis and clinical stage, as well as overall survival and replase-free survival of MM. We also found that ectopic expression of miR-365 inhibited MM cell proliferation and MM metastasis in vitro and in vivo. We further identified a novel mechanism of miR-365 to suppress MM growth and metastasis. NRP1 was proved to be a direct target of miR-365, using luciferase assay and western blot. NRP1 over-expression in miR-365 expressing cells could rescue invasion and growth defects of miR-365. In addition, miR-365 expression inversely correlated with NRP1 protein levels in MM. Conclusion: Our data suggest that miR-365 functions as a tumor suppressor in MM development and progression, and holds promise as a prognostic biomarker and potential therapeutic target for MM.     

Single step screening of monoclonal antibodies against interferon-gamma-induced surface molecules on human monocytes

Interferon-gamma (IFN-gamma) activation of human monocytes in vitro results in enhanced phagocytosis and cellular cytotoxicity. These enhanced effector functions are attributable, at least in part, to increased expression of recognition molecules on the plasma membrane. In this article we report a rapid screening procedure for the primary selection of monoclonal antibodies (mAbs) which bind to cell surface molecules, the expression of which is increased or decreased by IFN-gamma. The procedure is based on flow cytometric analysis of mixed cell populations. Mouse mAbs were prepared using human monocytes cultured for 40 h with 400 U/ml of IFN-gamma as the immunogen. The hybridoma supernatants were screened using mixtures of six cell populations, some of which were pretreated with IFN-gamma for 40 h. Cells included in the mixture were chosen for their distinctive light scatter profiles. mAbs of interest were identified by preferential binding to monocytes and increased or decreased binding to monocytes treated with IFN-gamma. This procedure allowed us to screen several hundred clones per day, and to immediately eliminate mAbs that bound to B cells, T cells, neutrophils, and several cell lines. We selected ten mAbs which bound to surface molecules on monocytes that were modulated by IFN-gamma. Further characterization of five of the initial ten mAbs revealed that mAb gamma M phi 22.2 and mAb gamma M phi 197.1 bind to the high affinity Fc receptor for IgG (Fc gamma RI). mAb gamma M phi 28.3 appears to bind to a class II histocompatibility antigen and mAb gamma M phi 150.3 and mAb gamma M phi 195.18 appear to have binding patterns to human leukocytes and cell lines which are distinct from previously described mAbs. This rapid and specific procedure for screening mAbs has broad application for selecting mAbs that are specific for any given cell type and/or for surface molecules that are modulated by any cytokine and other hormone.     

抗前列腺特异性膜抗原膜外区多肽单克隆抗体的研制及初步应用

目的建立前列腺特异性膜抗原（PSMA）膜外区多肽杂交瘤细胞株，并对其分泌的PSMA单克隆抗体进行初步鉴定，为PSMA的功能研究和人源化抗体的制备奠定基础，以求进一步用于前列腺癌的诊断和治疗。方法使用人工合成多肽免疫BABL／c小鼠，采用PEG融合技术建立杂交瘤细胞株，制备单克隆抗体。通过免疫荧光法、酶联免疫吸附法及斑点金标法确定单克隆抗体的交叉反应性、亲和力及免疫球蛋白的类型和亚类。结果获得两株可稳定分泌PSMA单克隆抗体的杂交瘤细胞，4F4为IsG1类，1F1为IgC3类。两株单抗均能识别LNCap细胞表达的PSMA蛋白，与不表达PSMA的PC-3、SP2／0等细胞无交叉反应。杂交瘤细胞株1F1培养上清效价为1：40。腹水效价为1：6400；而杂交瘤细胞株4F4培养上清效价为1：80。腹水效价为1：8000。结论成功地制备出两株抗PSMA单克隆抗体，均具有良好的特异性和亲和力，为进一步建立免疫分析方法。进行PSMA相关研究奠定了基础。     

细胞因子Midkine融合蛋白的表达及其单克隆抗体的制备与应用

目的:克隆细胞因子midkine(MK)基因,表达其融合蛋白,制备抗MK单克隆抗体(mAb)并检测MK在肿瘤细胞中的表达。方法:利用MK基因的特异性引物,通过RT-PCR从人肾癌组织mRNA中扩增人MKcDNA分子。将其定向克隆于原核表达载体中,在大肠杆菌中表达MS2-MK融合蛋白。以纯化的融合蛋白免疫BALB/c小鼠,用传统的杂交瘤技术,进行细胞融合、筛选、克隆化并制备mAb腹水。用ELISA法分析其Ig亚类,用免疫细胞化学染色法检测MK在肿瘤细胞中的表达。结果:成功地克隆出MK基因并表达了MS2-MK融合蛋白。通过免疫和筛选,获得2株分泌小鼠抗人MKmAb的杂交瘤细胞,其分泌的mAb的Ig亚类分别为IgG1和IgG2a。免疫细胞化学染色显示,2株mAb与人胃癌细胞株MGC803和胃癌组织呈强阳性反应。结论:在原核细胞中获得MS2-MK融合蛋白的表达,并制备出抗MK的mAb,为研究MK的生物学活性提供了条件。     

免疫亲和层析纯化大肠癌相关抗原

目的 :从培养的大肠癌细胞Hce 86 93中分离纯化并鉴定大肠癌相关抗原。方法 :利用流式细胞术选择高表达大肠癌相关抗原的大肠癌细胞系 ,分别用单去污及三去污裂解液裂解细胞。然后用 5株抗大肠癌单克隆抗体 (mAb)CYL 1～CYL 5进行Westernblot,分析与大肠癌细胞结合反应最强的mAb。以此mAb作为配基进行亲和层析纯化大肠癌相关抗原 ,纯化结果利用Westernblot法进行鉴定。结果 :大肠癌细胞系Hce 86 93上相关抗原的表达量最高 ;抗大肠癌mAbCYL 2与Hce 86 93的结合力最强。纯化所获与CYL 2特异结合的大肠癌相关抗原 ,Mr 约为 13× 10 3 。该抗原由Mr 为 6 0× 10 3 和70× 10 3 两种亚基组成。结论 :利用mAbCYL 2进行亲和层析 ,从大肠癌细胞系Hce 86 93中获得纯化的肿瘤相关抗原。     

鼠抗人CD28分子单克隆抗体的研制及生物学特性研究

目的 制备鼠抗人CD28分子的单克隆抗体（mAb),研究其在T细胞的活化、增殖及信号传导中的作用。方法 以小鼠淋巴瘤细胞转染人CD28基因的细胞株（CD28-T）为免疫原,采用B淋巴细胞杂交瘤技术,获取分泌特异性mAb的杂交瘤细胞株,以体内诱生法生产腹水,并以免疫亲和层析法对其纯化,以快速定性试纸法鉴定mAb的Ig亚类,竞争抑制法分析mAb识别的抗原表位,3H-TdR掺入法研究mAb对T细胞的刺激效应,结果 成功地获得了5株分泌特异性抗入CD28mAb的杂交瘤细胞株,鉴定的1株（克隆18G8）属IgG2a,腹水效价（流式细胞仪分析）达1：2400以上,该mAb能60%阻断标准鼠抗入CD28抗体与相应抗原的结合,提示其识别的抗原表位与标准mAb不完全相同,mAb18G8可取代B7-1分子介导的协同刺激信号,促进人外周血T细胞增殖（ST=7）。结论 18G8是12株功能性mAb,具有重要的研究和应用价值。     

人CD112(Nectin2/PRR2)单克隆抗体的制备和鉴定

目的：表达和纯化CD112 胞膜外区重组蛋白, 制备针对CD112胞膜外区的单克隆抗体（mAb）, 并且研究CD112的分布.方法：采用基因重组技术在真核系统表达CD112-Fc融合蛋白, 亲和层析法进行蛋白纯化;纯化的CD112-Fc融合蛋白免疫BALB/c小鼠, 杂交瘤技术建立分泌CD112 mAb的杂交瘤细胞株, 间接ELISA、 Western blot及FCM鉴定mAb 的特异性.用流式细胞术（FCM）检测 CD112 的细胞系分布.结果：构建了高效真核表达载体pIg3C-CD112, 表达并纯化了CD112-Fc融合蛋白, 其纯度大于 90%.以纯化重组蛋白为免疫原共制备9株分泌抗CD112 mAb的杂交瘤细胞株（命名为FMU-CD112.1 ～FMU-CD112.9）, 制备腹水并纯化 mAb.FMU-CD112.1、 3、 6和8能用于Western blot, FMU-CD112.1、 4、 6和8可用于 FCM.CD112细胞分布检测显示该分子主要分布在正常上皮及内皮细胞系、巨核细胞谱系和部分T细胞系, 并高表达于上皮及内皮来源的肿瘤、胶质瘤等细胞系.结论：成功地表达纯化了CD112-Fc融合蛋白并建立了稳定分泌CD112 mAb的杂交瘤细胞株, 为CD112的功能研究打下坚实的基础.